A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

NCT01388816 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Type II Hyperlipidemia

Interventions

DRUG: DRL-17822 or placebo

Sponsor

Dr. Reddy's Laboratories Limited

Collaborators

[object Object]